Systemic lupus erythematosus and risk of infection.

Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol. 2020 Jun 01;:1-12 Authors: Barber MRW, Clarke AE Abstract INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects almost every organ system and it is treated with immunomodulation and immunosuppression. SLE patients have an intrinsically dysfunctional immune system which is exacerbated by disease activity and leaves them vulnerable to infection. Treatment with immunosuppression increases susceptibility to infection, while hydroxychloroquine use decreases this risk. Infectious diseases are a leading cause of hospitalization and death. AREAS COVERED: This narrative review provides an overview of recent epidemiology and predictors of infections in SLE, delineates the risk of infection by therapeutic agent, and provides suggestions for risk mitigation. Articles were selected from Pubmed searches conducted between September 2019 and January 2020. EXPERT OPINION: Despite the large burden of infection, effective and safe preventative care such as universal hydroxychloroquine use and vaccination are underutilized. Future efforts should be directed to quality improvement, glucocorticoid reduction, and validation of risk indices that identify patients at the highest risk of infection. PMID: 32478627 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research

Related Links:

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies to multiple self-antigens, including heat shock proteins (HSP). Because of the increased expre...
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
Authors: Wang B, Chen S, Zheng Q, Liu Y, Shi G Abstract Rheumatic diseases are extremely heterogeneous diseases with substantial risks of morbidity and mortality, and there is a pressing need in developing more safe and cost-effective treatment strategies. Peptide-based vaccination is a highly desirable strategy in treating noninfection diseases, such as cancer and autoimmune diseases, and has gained increasing attentions. This review is aimed at providing a brief overview of the recent advances in peptide-based vaccination therapy for rheumatic diseases. Tremendous efforts have been made to develop effective pepti...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand. But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
AbstractThis guideline aims to describe the complement system and the functions of the constituent pathways, with  particular focus on primary immunodeficiencies (PIDs) and their diagnosis and management. The complement system is a crucial part of the innate immune system, with multiple membrane-bound and soluble components. There are three distinct enzymatic cascade pathways within the complement system, the classical, alternative and lectin pathways, which converge with the cleavage of central C3. Complement deficiencies account for ~5% of PIDs. The clinical consequences of inherited defects in the complement system...
Source: Journal of Clinical Immunology - Category: Allergy & Immunology Source Type: research
UCLA scientists have discovered one reason why autoimmune diseases are more prevalent in women than in men. While males inherit their mother ’s X chromosome and father’s Y chromosome, females inherit X chromosomes from both parents. New research, which shows differences in how each of those X chromosomes is regulated, suggests that the X chromosome that females get from their father may help to explain their more active immune system .“It’s been known for many years that women are more susceptible to autoimmune diseases than men are,” said lead study author Dr. Rhonda Voskuhl, a UCLA professor...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
This study aims to investigate the autoimmunity against oxLDL and a possible way to increase atheroprotection in SLE.
Source: Atherosclerosis - Category: Cardiology Authors: Tags: E-poster session Source Type: research
Abstract Type I Interferon gene expression has been shown to play an important role in the pathogenesis of several systemic autoimmune disorders, paving the way for its potential use as a surrogate marker or a therapeutic tool. While the concept of type I interferon signature and its correlation with clinical phenotypes and disease activity, along with anti-interferon targeted therapy have been vastly investigated in patients with systemic lupus erythematosus, there is a paucity of data concerning antiphospholipid syndrome patients. In this review, we summarize the current knowledge on the pathogenetic and clinica...
Source: Journal of Autoimmunity - Category: Allergy & Immunology Authors: Tags: J Autoimmun Source Type: research
Conclusion and Perspectives Being exquisitely regulated by “writers,” “erasers,” and “readers,” additional repelled proteins or miRNAs, m6A modification relates to nearly any step of mRNA metabolism, as well as ncRNA processing and circRNA translation. There is compelling evidence suggesting that m6A modification is especially critical in a variety of pathologic and physiologic immune responses including T cell homeostasis and differentiation, inflammation, and type I interferon production. Further results have indicated that aberrancies of interferon and Th17 frequencies in systemic lu...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, our results confirm the effects of belimumab on B cell subpopulations. These can be directly explained by the blockage of soluble BLyS interaction with BLyS-R. On the other hand, the effects on the composition of the T cell compartment are mild, which is not totally unexpected, since the intensity of BLyS-R expression by peripheral T cells is low (Ng et al., 2004). The principal limits of this study include the small sample size, presence of concomitant immunosuppressive therapies and low absolute cell number at baseline. Nevertheless, future studies on larger numbers of patients are needed to evaluate wheth...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Allergy & Immunology | Autoimmune Disease | Epidemiology | Hydroxychloroquine | Infectious Diseases | Lupus | Vaccines